Ontario source: bounded use
Skin Cancer Diagnosis, Treatment and Follow-Up Pathway Map supplies a Canadian implementation example for this summary. It must not be presented as the rule outside Ontario.
sources for this section:Ontario skin cancer pathway
Source-attributed clinical priorities
- Examine suspicious lesions systematically and document evolution, morphology, symptoms, size and site.
- Use dermoscopy where trained and arrange biopsy or referral according to suspected melanoma, keratinocyte cancer and local pathway.
- Escalate rapidly changing pigmented lesions, destructive lesions, high-risk sites and immunocompromised patients.
- Compare with previous photographs or lesion history because evolution is a key malignancy clue.
sources for this section:Ontario skin cancer pathway
Practical assessment and management workflow
1
Inspect the entire lesion and relevant skin and nodes and document size, color, border, ulceration and change.
2
Use dermoscopy when trained and photograph with scale and site identification.
3
Choose complete biopsy or direct specialist referral according to melanoma suspicion, site and local pathway.
4
Track pathology and ensure margin or staging follow-up is not lost between services.
sources for this section:Ontario skin cancer pathway
Safety, red flags and urgent escalation
- A rapidly changing pigmented lesion, destructive ulcer or suspicious node needs expedited assessment.
- Avoid superficial shave sampling when it would prevent reliable assessment of suspected melanoma depth.
- Immunocompromised patients and high-risk anatomic sites need a lower referral threshold.
sources for this section:Ontario skin cancer pathway
Confirm the local pathway before acting
Ontario is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:Ontario skin cancer pathway
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Ontario skin cancer pathway
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Ontario Health (Cancer Care Ontario)Skin Cancer Diagnosis, Treatment and Follow-Up Pathway MapVersion 2025.10 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.